Use of CYP2D6 inhibitors in combination therapies
OwnerR. Scott Obachinventor
Life of this patent
Estimating the term…
Abstract
This invention relates to the use of a CYP2D6 inhibitor in combination with a drug having CYP2D6 catalyzed metabolism, wherein the drug and the CYP2D6 inhibitor are not the same compound; and pharmaceutical compositions for said use.
Claims22
A method of administering a drug for which the major clearance mechanism in humans is CYP2D6 mediated oxidative biotransformation, or a pharmaceutically acceptable salt thereof, in combination with a CYP2D6 inhibitor, or a pharmaceutically acceptable salt thereof, to a human in need of the intended pharmaceutical activity of such drug, wherein said drug and said CYP2D6 inhibitor are not the same compound.
A pharmaceutical composition comprising:
- (a) a therapeutically effective amount of a drug for which the major clearance mechanism in humans is CYP2D6 mediated oxidative biotransformation, or a pharmaceutically acceptable salt thereof;
- (b) an amount of a CYP2D6 inhibitor, or a pharmaceutically acceptable salt thereof, that is effective in treating the disorder or condition for which the drug referred to in “a” is intended to treat;
- and
- (c) a pharmaceutically acceptable carrier;
- wherein said drug and said CYP2D6 inhibitor are not the same compound.
Dependencies are inferred from the claim text.